Toft Group Completes Executive Search for Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) in Hercules, CA

Executive search firm Toft Group has placed Dr. Jaime Humara as Vice President, LSG Marketing at Bio-Rad Laboratories, Inc. in Hercules, CA. He most recently served with Beckman Coulter, a leading life sciences and diagnostics product company, as Director of Global Strategic Marketing, Molecular Diagnostics. Dr. Humara brings over a decade of experience in marketing and product development, having worked in multiple roles for Thermo Fisher Scientific (formerly Life Technologies), most recently as the Senior Director, North America Regional Marketing which included leading all marketing programs for Life Technologies branded products in North America, of which there were over 50,000. He earned his doctorate in Plant Biotechnology and BS degree from the University of Oviedo in Asturias, Spain.

About Bio-Rad

Bio-Rad Laboratories, Inc. develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The Company employs more than 8,250 people worldwide and had revenues exceeding $2 billion in 2016.

Toft Group Completes Executive Search for LabCorp (NYSE: LH) in Burlington, NC

Executive search firm Toft Group has placed Dr. Mary A. Williamson as the Vice President of Laboratory Operations at LabCorp in Burlington, NC. She is a senior laboratory leader offering 20+ years of clinical experience. She most recently served as the Vice President of Scientific Affairs & Laboratory Operations at ACM Global Central Laboratory in Rochester, NY. She holds a PhD and Master’s in Toxicology from the University of Rochester School of Medicine & Dentistry.

About LabCorp

Laboratory Corporation of America® Holdings (NYSE: LH), an S&P 500 company, is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and develops technology-enabled solutions to change the way care is provided. With net revenue in excess of $8.5 billion in 2015, LabCorp’s 50,000 employees serve clients in 60 countries.

Toft Group Completes Chief Business Officer Search for GeneCentric Therapeutics in Durham, NC

GeneCentric Therapeutics, Inc., a precision medicine company dedicated to accelerating drug development by redefining the advanced classification of cancers, today announced the appointment of Walter M. Capone as Chief Business Officer. In his role as CBO, Mr. Capone will lead the expansion of pharmaceutical and biotech drug development collaborations involving GeneCentric’s Cancer Subtyping Platform (CSP™), and will oversee the company’s commercial strategy and growth.

“We are excited to have Walter join our strong leadership team,” said Chief Executive Officer Dr. Myla Lai-Goldman. “His expertise in drug development and commercialization will enable GeneCentric Therapeutics to actively expand its pharmaceutical and biotech company collaborations to advance therapeutic breakthroughs.”

Robin Toft, President and CEO of Toft Group said: “GeneCentric is a forward-thinking organization with an incredibly passionate leadership team. Walter will add great value to the organization, and will be a strong contributor to the continued growth of the company.”

Mr. Capone most recently served as CEO and President of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC), advancing industry, academic research, government agency and patient community collaborations to drive breakthroughs for patients. The launch of the landmark CoMMpassSM Study, support in advancing six new myeloma therapies to market, and expansion in innovative academic/industry partnerships were among his accomplishments. Prior to joining the MMRF, Mr. Capone had over 20 years of pharma/biotech leadership experience in the United States and internationally in the areas of oncology, immunology and infectious disease drug development and commercialization at Progenics Pharmaceuticals, Trimeris Inc., Triangle Pharmaceuticals, Bristol-Myers Squibb, Wyeth, and Lederle. He received his MBA from Columbia University Business School and BA from Brown University.

About Toft Group Executive Search

Toft Group Executive Search is “Changing the Future of Medicine, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market. We are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries. Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego, and Boston, we assist a wide range of local, national and international companies – from venture backed start-ups to Fortune 500 corporations.

About GeneCentric

GeneCentric Therapeutics, Inc. is a privately-held precision medicine company that is redefining the advanced classification of cancers through the development and commercialization of its proprietary Cancer Subtype Platform (CSP™). By defining subtypes of cancer, CSP™ can enable drug developers to better predict drug response and determine why drugs fail in late stage clinical trials. GeneCentric creates and applies technologies focused on enhancing, accelerating and de-risking the costly drug development process to enable its industry partners to advance therapies which obtain the best possible patient treatment outcomes. GeneCentric was founded in 2011 and is based in Durham, NC. In addition to Bristol-Myers Squibb, its investors include Hatteras Venture Partners and Laboratory Corporation of America.

Toft Group Ranked ‘Top 50 Executive Recruiter’ for 2017 by Hunt Scanlon Media

Toft Group Executive Search, a global life sciences and healthcare executive recruiting firm, announced it has been ranked in the Top 50 Executive Recruiting Firms by Hunt Scanlon Media, the most widely referenced, single source for information in the human capital sector.

Toft Group was one of eleven new companies ranked in the Top 50 this year with Hunt Scanlon Media describing the group as the largest, fastest growing, and leading boutique specialty executive search firms in the Americas. The Top 50 List collectively generated $3.1 billion in revenue for 2016, a record and a significant comeback since the Great Recession a decade ago. The article highlighted that the record growth was due to a massive industry shift away from identifying and recruiting leaders, to providing sophisticated talent solutions that integrate leadership consulting with executive search capabilities.

“To be recognized by Hunt Scanlon as one of the largest recruiting firms in the Americas for the first time is an honor and major milestone for Toft Group Executive Search,” commented Robin Toft, President & CEO. “We have an incredible team and are proud of their ability to deepen relationships with clients, continually delivering highly specialized leadership in areas where there is a significant talent shortage.

Scott A. Scanlon, founding chairman & CEO of Hunt Scanlon Media and editor-in-chief of this year’s rankings report, provided his insight on the booming industry, “…More companies are looking to search firms for a multitude of services – from succession planning and candidate assessments to onboarding and executive coaching.”

Toft Group has experienced significant revenue growth since it was established in 2010. Earlier this year, Toft Group was also ranked in Hunt Scanlon’s Top 50 Executive Search Firm in Life Sciences. For more information about Toft Group, visit www.thetoftgroup.com.

About Toft Group Executive Search

Toft Group Executive Search is “Changing the Future of Medicine, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market. Named a Top 150 Fastest Growing Private Company and a Top 50 Executive Search Firm in Life Sciences, we are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries.  Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego and Boston, we assist a wide range of local, national and international companies – from venture backed start-ups to Fortune 500 corporations.

About Hunt Scanlon Media

Hunt Scanlon Media has been informing the senior talent management sector for over 25 years. Our global news and intelligence data comes in many forms, including daily newswires, talent leadership reports, newsletter briefings and social media alerts. The privately-held company is headquartered in Greenwich, Conn.

Toft Group Completes Executive Search for Genalyte, Inc. in San Diego, CA

Executive search firm Toft Group has placed Mr. Michael O’Neil as Vice President, Product Marketing and Strategy at Genalyte, Inc. in San Diego, CA. Mr. O’Neil brings over a decade of experience in product innovation and market share growth, and is a senior leader in product development, strategy and marketing. He served in various leadership roles within Blue Shield of California, most recently as the Vice President, Product & Market Alignment where he oversaw product development, market intelligence, and market strategy, and was responsible for leading a transformation of business practices that increased membership growth and launched market leading provider partnership networks. . Mr. O’Neil earned his M.A. from Stanford University and his BA degree from Dartmouth.

About Genalyte, Inc.

Genalyte’s vision is to transform the doctor-patient relationship by bringing the doctor, the patient, and the lab together to provide results when they matter: Now. Genalyte’s platform is being designed with the goal of providing test results from a whole blood sample within fifteen minutes in the physician’s office. Providing diagnostic results at the time and place they are needed – when the patient is sitting in front of the doctor – has the potential to empower physicians, improve quality of care for patients, and reduce resource utilization across the healthcare system. Genalyte’s technology is based on a proprietary silicon biosensor design that is currently in use by pharmaceutical companies, contract research organizations and academic researchers.

Toft Group Completes Executive Search for Agilent Technologies, Inc. (NYSE: A) in Santa Clara, CA

Executive search firm Toft Group has placed Mr. Kenneth Hood as the Senior Director of Enterprise Regulatory Affairs for Agilent Technologies in Santa Clara, CA. Ken is a Regulatory Affairs leader offering 20 years within the medical device and diagnostics industries spanning multiple therapeutic areas. He joins Agilent from Hologic, Inc., where he served as Sr. Director of Regulatory Affairs. He earned an MBA from San Jose State University.

About Agilent Technologies, Inc.

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide.

Toft Group Completes Chief Medical Officer Search for Peloton Therapeutics, Inc. in Dallas, TX

Peloton Therapeutics, Inc., a drug discovery and development company focused on advancing novel small molecule cancer therapies, announced the appointment of Mohammad Hirmand, M.D., as Chief Medical Officer. Dr. Hirmand assumed his new role on the executive management team on May 1, 2017 and will lead the Company’s clinical drug development forward.

“Dr. Hirmand is a solid leader and clinician with an impressive track record of successfully developing novel medicines in oncology,” said John A. Josey, Ph.D., Peloton’s Chief Executive Officer. “He brings to Peloton a keen ability to focus and drive an asset to a successful outcome, from discovery to regulatory review, and he is well-versed in pharmaceutical partnering. We are delighted to welcome Mohammad to our team at this critical time.” Robin Toft, President and CEO of Toft Group said: “Peloton Therapeutics has an incredibly strong leadership team, and we have every confidence that Mohammad will make an exceptional contribution to the company’s continued growth and success.”

Dr. Hirmand most recently served as Chief Medical Officer at Medivation (recently acquired by Pfizer), where he played a vital role in advancing XTANDI® (enzalutamide) through clinical trials that led to its approval by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer. His responsibilities also included the in-licensing and global clinical development of the poly ADP ribose polymerase (PARP) inhibitor, talazoparib. Before Medivation, he was Senior Director of Clinical Development at Nuvelo, Inc. (now ARCA Biopharma), where he led the Clinical Operations, Clinical Data Management and Clinical Sciences/Medical Monitor staff. Prior to that, he served as Director of Oncology Development at SuperGen, Inc. (now Astex Pharmaceuticals, Inc.) and as Associate Director of Clinical Research at Amgen, Inc. (formerly Tularik, Inc.), where he led clinical development efforts for Tularik’s oncology trials. Early in his career, he was a Clinical Scientist and Manager of Market Development and Product Evaluation at Theravance Biopharma, Inc. Dr. Hirmand received his M.D. from Harvard Medical School and his B.A. in Biological Sciences and Economics from Cornell University.

“Peloton is working in an exciting and largely untapped area in the fight against cancer. The opportunity to advance medicines with unique and highly targeted mechanism of action, such as Peloton’s HIF-2α inhibitors, is particularly appealing,” said Dr. Hirmand. “I welcome the opportunity to join their effort to quickly and efficiently bring their novel medicines to underserved patients and the marketplace.”

About Toft Group Executive Search

Toft Group Executive Search is “Changing the Future of Medicine, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market. We are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries. Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego, and Boston, we assist a wide range of local, national and international companies – from venture backed start-ups to Fortune 500 corporations.

About Peloton Therapeutics

Peloton Therapeutics, Inc., is a clinical-stage biotechnology company that discovers and develops novel small molecule cancer therapies targeting unexploited molecular vulnerabilities. Peloton Therapeutics’ lead programs are small molecule inhibitors targeting hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of kidney and other cancers.

Toft Group Completes Executive Search for Multiple Myeloma Research Foundation in Norwalk, CT

Executive search firm Toft Group has placed Mr. Christopher Williams as Vice President, Business Development at the Multiple Myeloma Research Foundation in Norwalk, CT. Mr. Williams is a business development leader with a strong scientific background, specializing in the pharmaceutical and diagnostics space. He previously served as the Vice President of Business Development at WaveSense where he managed US commercialization strategy and product expansion. In addition, he also led business development for SkylineDx and served 8 years at PerkinElmer most recently as a Market Segment Leader, Oncology, but in addition held various scientific roles within the company. Mr. Williams earned his MS in Biochemistry and BS degree in Microbiology from Clemson University.

About the Multiple Myeloma Research Foundation (MMRF)

The mission of the Multiple Myeloma Research Foundation (MMRF) is to find a cure for multiple myeloma by relentlessly pursuing innovation that accelerates the development of next-generation treatments to extend the lives of patients. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c) (3) nonprofit organization, the MMRF is a world-recognized leader in cancer research. The MMRF continues to disrupt the industry today, as a pioneer and leader at the helm of new research efforts. Since its inception, the organization has raised over $330 million and directs nearly 90% of the total funds to research and related programs.

Toft Group Completes Executive Search for Agilent Technologies, Inc. (NYSE: A) in Santa Clara, CA

Executive search firm Toft Group has placed Ms. Nina Green as the General Manager, Companion Diagnostics for Agilent Technologies, Inc., in Carpinteria, CA. Ms. Green offers 30 years’ experience as an executive leader within the diagnostics and life science industries with expertise in growing existing businesses and entrepreneurial ventures, mergers, acquisitions and business integrations. She most recently served as the Chief Operating Officer for Clarient at GE Healthcare specializing in cancer diagnostics.

About Agilent Technologies, Inc.

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide.

Toft Group Completes Executive Search for Theravance BioPharma (NASDAQ: TBPH) in South San Francisco, CA

Executive search firm Toft Group has placed Mr. Sidney Bennett as the Associate Director, Marketing & Commercial Operations for Theravance BioPharma in South San Francisco, CA. Mr. Bennett brings over a decade of experience within marketing, strategy and product development. He previously served in various roles at Genentech, culminating to Senior Product Manager, Ocrelizumab Patient Marketing. He earned an MBA from Cornell University.

About Theravance BioPharma

Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that make a difference in the lives of patients suffering from serious illness.